Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b
Maternal immunization with the capsular polysaccharide (PRP) vaccine of Haemophilus influenzae type b has been shown to extend the time that protective levels of maternal antibody are detected in infants. In a randomized, blinded trial, PRP or placebo was administered uneventfully to 213 women in th...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1992-06, Vol.165 (Supplement-1), p.S134-S136 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S136 |
|---|---|
| container_issue | Supplement-1 |
| container_start_page | S134 |
| container_title | The Journal of infectious diseases |
| container_volume | 165 |
| creator | Glezen, W. Paul Englund, Janet A. Siber, George R. Six, Howard R. Turner, Connie Shriver, Diane Hinkley, Clark M. Falcao, Orceli |
| description | Maternal immunization with the capsular polysaccharide (PRP) vaccine of Haemophilus influenzae type b has been shown to extend the time that protective levels of maternal antibody are detected in infants. In a randomized, blinded trial, PRP or placebo was administered uneventfully to 213 women in the third trimester of pregnancy. Infants born to PRP recipients had significantly higher levels of antibody to PRP than did infants born to placebo recipients: 2.73 μg/ml compared with 0.33 μg/ml. It was estimated that infants of mothers who received the PRP vaccine would be protected for an average of 4 months compared to an average ofonly 2 months for those of mothers who received placebo. Infants were followed for invasive H. influenzae type b disease through the first year of life; none was detected. |
| doi_str_mv | 10.1093/infdis/165-Supplement_1-S134 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_72947864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30112313</jstor_id><sourcerecordid>30112313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-fbbeeb8d4f389adf9ef9623b08d0fd6d72abb9ecb04746e9214533ebfa030ff83</originalsourceid><addsrcrecordid>eNpNkFtPFTEURhujwSP4E0z6YHwbaKedXhJfzFE4GFQCaIgvtZ3ZzSl2LrQz0cOvd8gQ8GnvZH37koXQW0oOKdHsKHS-CfmIiqq4nIYhQgvdaGhxSRl_hla0YrIQgrLnaEVIWRZUaf0Svcr5hhDCmZB7aI9WSlEuV-jXFztC6mzEp207deHOjqHv8J8wbvG4Bby2Q56iTfi8j7ts63prU2gA_5jb0AH2fcIbC20_bEOcMp6fixN0dxbw1W4A7A7QC29jhtcPdR99P_50td4UZ99OTtcfzoqaSTUW3jkApxrumdK28Rq8FiVzRDXEN6KRpXVOQ-0Il1yALimvGAPnLWHEe8X20btl75D62wnyaNqQa4jRdtBP2chSc6kEn4Pvl2Cd-pwTeDOk0Nq0M5SYe8FmEWxmweZ_weZe8Dz-5uHO5FponoYXo0_8Jo99esSMUFoyymZeLDzkEf4-cpt-GyGZrMzm-qf5ys8_XpBraT6zfyO7mTY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72947864</pqid></control><display><type>article</type><title>Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><creator>Glezen, W. Paul ; Englund, Janet A. ; Siber, George R. ; Six, Howard R. ; Turner, Connie ; Shriver, Diane ; Hinkley, Clark M. ; Falcao, Orceli</creator><creatorcontrib>Glezen, W. Paul ; Englund, Janet A. ; Siber, George R. ; Six, Howard R. ; Turner, Connie ; Shriver, Diane ; Hinkley, Clark M. ; Falcao, Orceli</creatorcontrib><description>Maternal immunization with the capsular polysaccharide (PRP) vaccine of Haemophilus influenzae type b has been shown to extend the time that protective levels of maternal antibody are detected in infants. In a randomized, blinded trial, PRP or placebo was administered uneventfully to 213 women in the third trimester of pregnancy. Infants born to PRP recipients had significantly higher levels of antibody to PRP than did infants born to placebo recipients: 2.73 μg/ml compared with 0.33 μg/ml. It was estimated that infants of mothers who received the PRP vaccine would be protected for an average of 4 months compared to an average ofonly 2 months for those of mothers who received placebo. Infants were followed for invasive H. influenzae type b disease through the first year of life; none was detected.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/165-Supplement_1-S134</identifier><identifier>PMID: 1588147</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Antibodies ; Antibodies, Bacterial - blood ; Bacterial Capsules ; Bacterial Vaccines - administration & dosage ; Bacterial Vaccines - immunology ; Double-Blind Method ; Enzyme linked immunosorbent assay ; Female ; Fetal Blood - immunology ; Follow-Up Studies ; Haemophilus Infections - prevention & control ; Haemophilus influenzae - immunology ; Haemophilus influenzae type b ; Haemophilus Vaccines ; Humans ; Immunity, Maternally-Acquired ; Immunization ; Immunization - methods ; Immunoglobulin G - biosynthesis ; Immunoglobulin G - blood ; Infant, Newborn ; Infants ; Nervous system diseases ; Placebos ; Polysaccharides ; Polysaccharides, Bacterial - administration & dosage ; Polysaccharides, Bacterial - immunology ; Pregnancy ; Radioimmunoassay ; Session IV: Prevention of Haemophilus influenzae Type b Disease by Vaccination ; Vaccination ; Women</subject><ispartof>The Journal of infectious diseases, 1992-06, Vol.165 (Supplement-1), p.S134-S136</ispartof><rights>Copyright 1992 The University of Chicago</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-fbbeeb8d4f389adf9ef9623b08d0fd6d72abb9ecb04746e9214533ebfa030ff83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30112313$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30112313$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,778,782,801,27911,27912,58004,58237</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1588147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glezen, W. Paul</creatorcontrib><creatorcontrib>Englund, Janet A.</creatorcontrib><creatorcontrib>Siber, George R.</creatorcontrib><creatorcontrib>Six, Howard R.</creatorcontrib><creatorcontrib>Turner, Connie</creatorcontrib><creatorcontrib>Shriver, Diane</creatorcontrib><creatorcontrib>Hinkley, Clark M.</creatorcontrib><creatorcontrib>Falcao, Orceli</creatorcontrib><title>Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Maternal immunization with the capsular polysaccharide (PRP) vaccine of Haemophilus influenzae type b has been shown to extend the time that protective levels of maternal antibody are detected in infants. In a randomized, blinded trial, PRP or placebo was administered uneventfully to 213 women in the third trimester of pregnancy. Infants born to PRP recipients had significantly higher levels of antibody to PRP than did infants born to placebo recipients: 2.73 μg/ml compared with 0.33 μg/ml. It was estimated that infants of mothers who received the PRP vaccine would be protected for an average of 4 months compared to an average ofonly 2 months for those of mothers who received placebo. Infants were followed for invasive H. influenzae type b disease through the first year of life; none was detected.</description><subject>Antibodies</subject><subject>Antibodies, Bacterial - blood</subject><subject>Bacterial Capsules</subject><subject>Bacterial Vaccines - administration & dosage</subject><subject>Bacterial Vaccines - immunology</subject><subject>Double-Blind Method</subject><subject>Enzyme linked immunosorbent assay</subject><subject>Female</subject><subject>Fetal Blood - immunology</subject><subject>Follow-Up Studies</subject><subject>Haemophilus Infections - prevention & control</subject><subject>Haemophilus influenzae - immunology</subject><subject>Haemophilus influenzae type b</subject><subject>Haemophilus Vaccines</subject><subject>Humans</subject><subject>Immunity, Maternally-Acquired</subject><subject>Immunization</subject><subject>Immunization - methods</subject><subject>Immunoglobulin G - biosynthesis</subject><subject>Immunoglobulin G - blood</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Nervous system diseases</subject><subject>Placebos</subject><subject>Polysaccharides</subject><subject>Polysaccharides, Bacterial - administration & dosage</subject><subject>Polysaccharides, Bacterial - immunology</subject><subject>Pregnancy</subject><subject>Radioimmunoassay</subject><subject>Session IV: Prevention of Haemophilus influenzae Type b Disease by Vaccination</subject><subject>Vaccination</subject><subject>Women</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkFtPFTEURhujwSP4E0z6YHwbaKedXhJfzFE4GFQCaIgvtZ3ZzSl2LrQz0cOvd8gQ8GnvZH37koXQW0oOKdHsKHS-CfmIiqq4nIYhQgvdaGhxSRl_hla0YrIQgrLnaEVIWRZUaf0Svcr5hhDCmZB7aI9WSlEuV-jXFztC6mzEp207deHOjqHv8J8wbvG4Bby2Q56iTfi8j7ts63prU2gA_5jb0AH2fcIbC20_bEOcMp6fixN0dxbw1W4A7A7QC29jhtcPdR99P_50td4UZ99OTtcfzoqaSTUW3jkApxrumdK28Rq8FiVzRDXEN6KRpXVOQ-0Il1yALimvGAPnLWHEe8X20btl75D62wnyaNqQa4jRdtBP2chSc6kEn4Pvl2Cd-pwTeDOk0Nq0M5SYe8FmEWxmweZ_weZe8Dz-5uHO5FponoYXo0_8Jo99esSMUFoyymZeLDzkEf4-cpt-GyGZrMzm-qf5ys8_XpBraT6zfyO7mTY</recordid><startdate>19920601</startdate><enddate>19920601</enddate><creator>Glezen, W. Paul</creator><creator>Englund, Janet A.</creator><creator>Siber, George R.</creator><creator>Six, Howard R.</creator><creator>Turner, Connie</creator><creator>Shriver, Diane</creator><creator>Hinkley, Clark M.</creator><creator>Falcao, Orceli</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920601</creationdate><title>Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b</title><author>Glezen, W. Paul ; Englund, Janet A. ; Siber, George R. ; Six, Howard R. ; Turner, Connie ; Shriver, Diane ; Hinkley, Clark M. ; Falcao, Orceli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-fbbeeb8d4f389adf9ef9623b08d0fd6d72abb9ecb04746e9214533ebfa030ff83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Antibodies</topic><topic>Antibodies, Bacterial - blood</topic><topic>Bacterial Capsules</topic><topic>Bacterial Vaccines - administration & dosage</topic><topic>Bacterial Vaccines - immunology</topic><topic>Double-Blind Method</topic><topic>Enzyme linked immunosorbent assay</topic><topic>Female</topic><topic>Fetal Blood - immunology</topic><topic>Follow-Up Studies</topic><topic>Haemophilus Infections - prevention & control</topic><topic>Haemophilus influenzae - immunology</topic><topic>Haemophilus influenzae type b</topic><topic>Haemophilus Vaccines</topic><topic>Humans</topic><topic>Immunity, Maternally-Acquired</topic><topic>Immunization</topic><topic>Immunization - methods</topic><topic>Immunoglobulin G - biosynthesis</topic><topic>Immunoglobulin G - blood</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Nervous system diseases</topic><topic>Placebos</topic><topic>Polysaccharides</topic><topic>Polysaccharides, Bacterial - administration & dosage</topic><topic>Polysaccharides, Bacterial - immunology</topic><topic>Pregnancy</topic><topic>Radioimmunoassay</topic><topic>Session IV: Prevention of Haemophilus influenzae Type b Disease by Vaccination</topic><topic>Vaccination</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glezen, W. Paul</creatorcontrib><creatorcontrib>Englund, Janet A.</creatorcontrib><creatorcontrib>Siber, George R.</creatorcontrib><creatorcontrib>Six, Howard R.</creatorcontrib><creatorcontrib>Turner, Connie</creatorcontrib><creatorcontrib>Shriver, Diane</creatorcontrib><creatorcontrib>Hinkley, Clark M.</creatorcontrib><creatorcontrib>Falcao, Orceli</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glezen, W. Paul</au><au>Englund, Janet A.</au><au>Siber, George R.</au><au>Six, Howard R.</au><au>Turner, Connie</au><au>Shriver, Diane</au><au>Hinkley, Clark M.</au><au>Falcao, Orceli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1992-06-01</date><risdate>1992</risdate><volume>165</volume><issue>Supplement-1</issue><spage>S134</spage><epage>S136</epage><pages>S134-S136</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Maternal immunization with the capsular polysaccharide (PRP) vaccine of Haemophilus influenzae type b has been shown to extend the time that protective levels of maternal antibody are detected in infants. In a randomized, blinded trial, PRP or placebo was administered uneventfully to 213 women in the third trimester of pregnancy. Infants born to PRP recipients had significantly higher levels of antibody to PRP than did infants born to placebo recipients: 2.73 μg/ml compared with 0.33 μg/ml. It was estimated that infants of mothers who received the PRP vaccine would be protected for an average of 4 months compared to an average ofonly 2 months for those of mothers who received placebo. Infants were followed for invasive H. influenzae type b disease through the first year of life; none was detected.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>1588147</pmid><doi>10.1093/infdis/165-Supplement_1-S134</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1992-06, Vol.165 (Supplement-1), p.S134-S136 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72947864 |
| source | MEDLINE; Jstor Complete Legacy |
| subjects | Antibodies Antibodies, Bacterial - blood Bacterial Capsules Bacterial Vaccines - administration & dosage Bacterial Vaccines - immunology Double-Blind Method Enzyme linked immunosorbent assay Female Fetal Blood - immunology Follow-Up Studies Haemophilus Infections - prevention & control Haemophilus influenzae - immunology Haemophilus influenzae type b Haemophilus Vaccines Humans Immunity, Maternally-Acquired Immunization Immunization - methods Immunoglobulin G - biosynthesis Immunoglobulin G - blood Infant, Newborn Infants Nervous system diseases Placebos Polysaccharides Polysaccharides, Bacterial - administration & dosage Polysaccharides, Bacterial - immunology Pregnancy Radioimmunoassay Session IV: Prevention of Haemophilus influenzae Type b Disease by Vaccination Vaccination Women |
| title | Maternal Immunization with the Capsular Polysaccharide Vaccine for Haemophilus influenzae Type b |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A28%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maternal%20Immunization%20with%20the%20Capsular%20Polysaccharide%20Vaccine%20for%20Haemophilus%20influenzae%20Type%20b&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Glezen,%20W.%20Paul&rft.date=1992-06-01&rft.volume=165&rft.issue=Supplement-1&rft.spage=S134&rft.epage=S136&rft.pages=S134-S136&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/165-Supplement_1-S134&rft_dat=%3Cjstor_proqu%3E30112313%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72947864&rft_id=info:pmid/1588147&rft_jstor_id=30112313&rfr_iscdi=true |